CareDx Finalizes Acquisition of Naveris to Enter High-Growth Oncology Diagnostics
TEM•On July 2, CareDx finalized its acquisition of Naveris, a specialty oncology diagnostics firm, adding imaging-based assays to its portfolio. The deal positions CareDx to leverage its transplant diagnostics network to target a high-growth oncology market segment.
1. Acquisition Details
On July 2, 2026, CareDx completed its purchase of Naveris, marking its first foray into specialty oncology diagnostics. Naveris’s imaging-based assays and analytical platform will be incorporated into CareDx’s existing operational framework.
2. Strategic Rationale
The acquisition extends CareDx’s leadership beyond transplant diagnostics, enabling cross-selling opportunities to its established customer base. Entry into the specialty oncology segment taps a market projected to grow double digits annually.
3. Integration Plans
CareDx intends to integrate Naveris operations by the end of Q4 2026 and target the first joint product launch in early 2027. The company aims to align R&D, sales and regulatory pathways to accelerate oncology assay rollout.
